Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?. Issue 3 (4th November 2021)

• Record Type: Journal Article
• Authors: Rentroia‐Pacheco, Barbara; Tjien‐Fooh, Félicia J.; Quattrocchi, Enrica; Kobic, Ajdin; Wever, Renske; Bellomo, Domenico; Meves, Alexander; Hieken, Tina J.
• Is Part Of: Journal of surgical oncology. Volume 125:Issue 3(2022)
• Page Start: 516
• Page End: 524
• Publication Date: 2021-11-04
• Subjects: melanoma -- non‐sentinel lymph node -- sentinel lymph node; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26736
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background and Objectives: Of clinically node‐negative (cN0) cutaneous melanoma patients with sentinel lymph node (SLN) metastasis, between 10% and 30% harbor additional metastases in non‐sentinel lymph nodes (NSLNs). Approximately 80% of SLN‐positive patients have a single positive SLN. Methods: To assess whether state‐of‐the‐art clinicopathologic models predicting NSLN metastasis had adequate performance, we studied a single‐institution cohort of 143 patients with cN0 SLN‐positive primary melanoma who underwent subsequent completion lymph node dissection. We used sensitivity (SE) and positive predictive value (PPV) to characterize the ability of the models to identify patients at high risk for NSLN disease. Results: Across Stage III patients, all clinicopathologic models tested had comparable performances. The best performing model identified 52% of NSLN‐positive patients (SE = 52%, PPV = 37%). However, for the single SLN‐positive subgroup (78% of cohort), none of the models identified high‐risk patients (SE > 20%, PPV > 20%) irrespective of the chosen probability threshold used to define the binary risk labels. Thus, we designed a new model to identify high‐risk patients with a single positive SLN, which achieved a sensitivity of 49% (PPV = 26%). Conclusion: For the largest SLN‐positive subgroup, those with a single positive SLN, current model performance is inadequate. New approaches are needed to better estimate nodal disease burden of these patients.